StockData
Silexion Therapeutics Corp logo

Silexion Therapeutics Corp (SLXN) stock

SLXNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as SLXNW
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 6/30
$1.65−0.11 (-6.25%)

Close on Nov 17, 2026Market cap $995.04KP/E –Yield –

Silexion Therapeutics enterprise value

Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.

Silexion Therapeutics's enterprise value was $1.58M on Nov 11, 2026, against $2.11B a year earlier. Over the last 3 years it ranged from -$4.08M to $488.16B, with a median of $365.88M.

Enterprise Value at the end of each year

PeriodPeriod endValueChange
2026Nov 11, 2026$1.58M-99.9%
2025Dec 31, 2025$1.43B+139.7%
2024Dec 31, 2024$597.15M–

More Silexion Therapeutics figures

See a number that looks wrong?